Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates
Stéphane Pillet(Medicago (Canada)), Brian J. Ward(McGill University Health Centre)
Cited by 59